Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, November 1, 2012

New hope for survivors of stroke and traumatic brain injury

This drug was earlier referenced here and because it seemed to be all anectdotal I didn't trust it.  If you have any form of reporter background ask for the full report, I'm no longer the Newsfeed editor for StrokeNet. The full-text article is available to journalists on request.The authors are also available for interviews.  I do hope this explains TNF and its reduction.
http://www.springer.com/about+springer/media/springer+select?SGWID=0-11001-6-1394543-0
Single dose of etanercept targets brain inflammation years after damage.

A new ground-breaking study about to be published in the Adis journal CNS Drugs provides clinical evidence that, for the first time, chronic neurological dysfunction from stroke or traumatic brain injury can rapidly improve following a single dose of a drug that targets brain inflammation, even years after the stroke or traumatic event.

The observational study¹ of 629 patients, conducted over the course of nearly two years, documents a diverse range of positive effects, including statistically significant rapid clinical improvement in motor impairment, spasticity, cognition, etc. in the stroke group, with a similar pattern of improvement seen in the traumatic brain injury (TBI) group. The study involved 617 patients treated an average of 42 months after stroke and 12 patients treated an average of 115 months after TBI, long after further spontaneous meaningful recovery would be expected.

The study was conducted at the Institute of Neurological Recovery (INR) in the USA.

The drug utilized was etanercept, a therapeutic that selectively binds and neutralizes an inflammatory immune molecule that may remain elevated for years following stroke. Etanercept was administered utilizing a novel delivery method, invented by Edward Tobinick M.D., lead author of the study.

"These results represent a sea change in the therapeutic possibilities for stroke and TBI patients," said Steven Ralph PhD, Associate Professor at Griffith University School of Medical Science in Australia. "Rarely do we see such a radical breakthrough in medical treatment as this for stroke. A previous example was the advance with thrombolytic therapy using drugs such as tissue plasminogen activator (t-PA) for the treatment of acute stroke with their significant impact when applied at the early stages. However, no similar treatment has existed for chronic stroke until now."

Professor Ralph recently led a team of physicians to the INR for training in the new etanercept delivery method, prior to their initiation of randomized trials in Australia. "Our team observed, first hand, rapid clinical improvement in stroke patients following this brief office treatment," said Professor Ralph.

In an accompanying editorial², Professor Ian Clark, a world expert on tumor necrosis factor (TNF) and brain dysfunction, discusses the science underlying the novel treatment method and clinical results. The high prevalence of chronic post-stroke and post-TBI neurological disability, with millions of individuals affected worldwide, highlights the study's significance.

1 comment:

  1. Dean, this study, like most are solely authored by Dr.Edward Tobinick, Dermatologist, Institute of Laser Medicine (hair removal) who also are the same staff and home of Institute of Neurological Recovery which also went under the name Institute for Neurological Research. Tobinick began making claims in 1998 for the off-label use of the then new rhumatoid arthritis drug Etanercept (Enbrel). Tobinick promoted the use of this drug for disc-related conditions such as chronic back pain. Tobinick created his own 'patented' administration of the drug and called it DiskCure with claims of relief within minutes. Tobinick advertised the treatment and charged patients thousands of dollars for this 'unique' treatment. Tobinick self autored studies to support these claims. A few years later Tobinick played the same trick, this time it was Alzheimer's, and after a number of years of causing havoc, Tobinick would appear to have prioritized his new target STROKE and Traumatic Brain Injury. A new patient can expect to pay around $4500 for an intitial consultation and 1st injection. Etanercept (Enbrel) carries a Remember a vial of Etanercept (Enbrel) costs about $230. Just because it is expensive, does not mean it works. These scams cost some money to run. In recent years I have observed Australians being targetted successfully by Tobinick with his scams be they for Alzheimer's or STROKE etc. Here are a list of chronic conditions which Tobinick claims to treat.

    Alzheimer’s Disease
    Traumatic Brain Injury
    Recovery after Stroke
    Vascular Dementia
    Frontotemporal Dementia
    Primary Progressive Aphasia

    Etanercept (Enbrel) carries a Boxed Warning
    http://pi.amgen.com/united_states/enbrel/derm/enbrel_pi.pdf

    Challenging Tobinick's claims and practices feels like a gnat fighting on the back of an elephant, but maybe someday the past will catch up with Dr. Edward Lewis Tobinick, Dermatologist.

    ReplyDelete